This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
CRA’s Lev Gerlovin and co-authors Walter Colasante and Pascale Diesel published a series of three articles in Cell & Gene on emerging gene and cell therapies and their impact on the market.
Read the full series below:
In this installment, we examine the relationship between launch prices in France and disease prevalence as reported in the Haute Autorité de Santé assessments.
As part of the CRA Life Sciences series on leveraging RADAR, our orphan drug data repository, we analyzed the relationship between annual list prices achieved
CRA is a proud sponsor of the event, back for its 8th edition. This half-day, high-impact conference brings together top arbitrators, counsel, experts and...
CRA is a proud sponsor of Europe’s largest congress in market access, pricing and evidence featuring 250 speakers, 10 tracks and 1500+ attendees from pharma,...
